Barzolvolimab met every Phase 3 CSU goal, with 42–54% complete responses. Shares still fell on high expectations, thin safety detail, and oral/injectable rivals.
Celldex discontinues barzolvolimab development in prurigo nodularis after its Phase 2 study failed to meet the primary endpoint and key secondary endpoints.
The acquisition would add a longer-acting alternative to Dupixent for inflammatory diseases.
Barclays boosts Celldex Therapeutics on strong drug outlook; higher success odds and sales expectations.
Wolfe Research upgrades Celldex Therapeutics to Outperform from Peer Perform, citing stronger 2026 catalysts and depressed valuation for rebound potential.
Celldex stopped barzolvolimab for eosinophilic esophagitis after it failed to improve symptoms, despite depleting mucosal mast cells. The company will now explore other GI diseases driven by mast cells where the antibody might be effective.
